Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12515
Title: | Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. | Austin Authors: | Fabris, Bruno;Jackson, B ;Cubela, R B;Mendelsohn, Frederick AO;Johnston, Colin I | Affiliation: | Medicine (University of Melbourne) | Issue Date: | 1-Apr-1989 | Publication information: | Clinical and Experimental Pharmacology & Physiology; 16(4): 309-13 | Abstract: | 1. The pharmacokinetics of angiotensin converting enzyme (ACE) inhibition in rat heart and lung was evaluated in vitro and ex vivo. 2. Radioinhibitor [125I]-351A binding displacement was used to assess the relative potency of six ACE-inhibitors (CI906, CGS14831, S9780, 351A, MK521, SQ27519) in rat heart and lung homogenates, and estimate equilibrium association constant (Ka). 3. Following oral administration of 0.3 mg/kg of Quinapril (CI928) specific binding of [125I]-351A to ACE was measured in rat heart. 4. Ka for binding to ACE of each inhibitor was significantly higher in right and left atrium than in lung (P less than 0.05) or the right and left ventricle (P less than 0.005). These differences did not affect the degree or time course of inhibition in vivo in the rat myocardial ACE following Quinapril treatment. 5. Rank order of potency of the ACE inhibitors tested was CI906 = CGS14831 greater than S9780 greater than 351A greater than MK521 greater than SQ27519 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/12515 | ORCID: | Journal: | Clinical and Experimental Pharmacology & Physiology | URL: | https://pubmed.ncbi.nlm.nih.gov/2545394 | Type: | Journal Article | Subjects: | Angiotensin-Converting Enzyme Inhibitors.pharmacology Animals Heart.drug effects In Vitro Techniques Iodine Radioisotopes.diagnostic use Lung.metabolism Male Myocardium.enzymology Peptidyl-Dipeptidase A.metabolism Rats Rats, Inbred Strains |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.